- Upgrade of the Theraxium Platform with the integration of the Zendesk software suite to power state-of-the-art global customer support services
- Highly personalized support provided for patients and healthcare professionals using Voluntis’ digital therapeutics
- Improved scalability of Voluntis’ operations by supporting the commercial rollout of the growing number of solutions co-developed with life sciences partners in new geographies
Voluntis (Euronext Growth Paris, Ticker: ALVTX – ISIN: FR0004183960)a leader in digital therapeutics, today announces the upgrade of its global customer support infrastructure in collaboration with customer service software company Zendesk.
Thanks to the new collaboration, Voluntis will leverage Zendesk’s capabilities to integrate and streamline the support services it provides for its pharma partners as part of the commercialization of co-developed digital therapeutics and in full compliance with applicable regulations.
The new support infrastructure will notably ensure a better coordination of all activities related to support and maintenance of its digital therapeutics thanks to user assistance services including technical support, complaint handling and device vigilance services regrouped under a unified platform. It will also offer new abilities to enhance self-service and omni-channel support options for patients and healthcare professionals. Furthermore, new data-driven capabilities for fostering continuous product and process improvement have been integrated into the platform.
The new service infrastructure is designed to be compliant with HIPAA, GDPR, SOC 2 Type II, ISO 27001 standards, in line with Voluntis’s global compliance and quality policies.
“We are glad to offer state-of-the-art global support capabilities to our life sciences partners in conjunction with the operation of our digital therapeutics. Thanks to our collaboration with Zendesk, an industry leader in the field of customer service, we look forward to delivering optimal treatment experiences to patients and their care teams around the world”.Pierre Leurent, Chief Executive Officer, Voluntis.
Next meeting: publication of the 2020 annual results on March 30, 2021, after the close of trading.
Voluntis creates digital therapeutics that empower people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Voluntis’ solutions, combining mobile and web apps, use clinical algorithms to deliver personalized recommendations to patients and their care teams. For example, these recommendations are used to adjust treatment dosage, manage side effects or monitor symptoms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in oncology and diabetes. Voluntis has long-standing partnerships with leading life science companies. Based in Cambridge, MA, and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.